- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01068210
Lung Cancer Exercise Training Study
April 18, 2025 updated by: Memorial Sloan Kettering Cancer Center
Lung Cancer Exercise Training Study: A Randomized Trial of Aerobic Training, Resistance Training, or Both in Lung Cancer Patients
The purpose of the study is look at the effects of different types of exercise training with a stretching group and its effect on lung cancer patients.
Subjects will take part in a 16 week training intervention that can consist of aerobic, resistance, aerobic & resistance, or a control group.
Pre and Post testing will include stress tests, echos, blood, and urine samples.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
110
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Signed informed consent prior to initiation of study-related procedures
- Age 21 - 80 years
- Weight < 205 kgs
- ECOG ≤ 1
- Diagnosed with histologically confirmed lung cancer, regardless of disease stage and receiving any prior line of any therapy in the context of metastatic disease
- An interval of at least three months following the completion of primary resection, if appropriate
- An interval of no longer than ten years following completion of primary therapy, if appropriate
- Life expectancy ≥ 4 months
- Performing less than 150 minutes of structured moderate-intensity or strenuous-intensity exercise per week
- Exercise intolerance (i.e., patients must have a VO2peak below that predicted for active age and sex-matched individuals)
- Willing to be randomized to one of the study arms
- Willing to commit to the study program and comply with all related protocol procedures
Able to achieve an acceptable peak baseline CPET, as defined by any of the following criteria:
- achieving a plateau in oxygen consumption, concurrent with an increase in power output;
- a respiratory exchange ratio ≥ 1.10;
- attainment of maximal predicted heart rate (HRmax) (i.e., within 10 bpm of age-predicted HRmax [HRmax = 220-Age[years]);
- volitional exhaustion, as measured by a rating of perceived exertion (RPE) ≥ 18 on the BORG scale.
- Able to complete an acceptable baseline CPET in the absence of high risk ECG findings or other inappropriate response to exercise as determined by the PI.
- Ability to achieve and complete an acceptable baseline one-repetition maximum muscular strength test as defined by the effective execution of protocol-specific joint and muscle ranges of motion without remarkable signs or symptoms of pain, discomfort or distress.
Exclusion Criteria:
- Presence of a concurrent, actively treated other malignancy, or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer);
- Room air desaturation at rest ≤ 85%;
- Mental impairment leading to inability to cooperate.
Any of the following absolute contraindications to cardiopulmonary exercise testing:
- Acute myocardial infarction (within 3-5 days of any planned study procedures);
- Unstable angina;
- Uncontrolled arrhythmia causing symptoms or hemodynamic compromise;
- Recurrent syncope;
- Active endocarditis;
- Acute myocarditis or pericarditis;
- Symptomatic severe aortic stenosis;
- Uncontrolled heart failure;
- Acute (within 3 months) pulmonary embolus or pulmonary infarction;
- Thrombosis of lower extremities;
- Suspected dissecting aneurysm;
- Uncontrolled asthma;
- Pulmonary edema;
- Respiratory failure;
- Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Aerobic Training
A customized and supervised endurance exercise training program that will last 4 months (16 weeks).
The regimen will be tailored to the individual fitness level.
The exercise program will consist of three supervised sessions per week.
During each session, the participant will cycle on a stationary bicycle at moderate intensity for approximately 30-60 minutes.
|
The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training.
All the exercise interventions are designed such that participants begin exercising at a low intensity (~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (~70%-100% VO2peak / ~70-85% 1RM) when appropriate.
All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.
|
|
Experimental: Resistance Training
A customized and supervised resistance exercise training program that will last 4 months (16 weeks).
Resistance training will be performed on stationary weight machines, modification in equipment may be made by Exercise Physiologist.
Patients will be progressively trained to perform two to three sets of 75-85% of maximal strength The participant will be trained to perform different resistance exercise, alternating between lower and upper body muscle groups.
The exercise program will consist of three supervised sessions per week.
Each session will last approximately 30-60 minutes.
|
The ultimate goal for resistance training alone is 3 resistance training session/week at an intensity above 50% to 85% of 1-RM for 30-60 minutes/session.
Resistance trainings will be performed on stationary weight machines, modification in equipment may be made by Exercise Physiologist.
Participants will be progressively trained to perform two to three sets of 75-85% of maximal strength.
|
|
Experimental: Combined Aerobic and Resistance Training
A customized and supervised endurance exercise training program that will last 4 months (16 weeks).
The regimen will be tailored to the individual fitness level, and will be a combination of Arm A and Arm B, described above.
At each session, the participant will complete aerobic training on a stationary bicycle and also resistance training using stationary weight machines.
The exercise program will consist of three supervised sessions per week.
Each session will last approximately 30-90 minutes.
|
The ultimate goal will be three combined exercise sessions per week at an intensity above 50% VO2speak and above 50% 1-RM for aerobic and resistance training, respectively for 30-90 minutes/session.
|
|
Active Comparator: Progressive Stretching Group (Attention-Control)
A customized and supervised progressive stretching program that will last 4 months (16 weeks).
The progressive stretching program will consist of a series of stretching exercises alternating between lower and upper body muscle groups/joints.
This program will consist of three exercise sessions a week.
Each session will last approximately 30-60 minutes.
|
The ultimate goal for the progressive stretching program is 3 individual stretching sessions.
All sessions are required to be supervised.
Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles.
This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in VO2peak (on Exercise Capacity)
Time Frame: 17 weeks
|
To compare the efficacy of different types of exercise training modalities, relative to progressive stretching (attention control group)
|
17 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Lee Jones, PhD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2015
Primary Completion (Actual)
March 29, 2024
Study Completion (Actual)
March 29, 2024
Study Registration Dates
First Submitted
February 11, 2010
First Submitted That Met QC Criteria
February 11, 2010
First Posted (Estimated)
February 12, 2010
Study Record Updates
Last Update Posted (Actual)
May 4, 2025
Last Update Submitted That Met QC Criteria
April 18, 2025
Last Verified
March 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-215
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer Institute; MedWaves, IncRecruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedStage IV Lung Cancer | Stage III Lung Cancer | Stage I Lung Cancer | Stage II Lung CancerUnited States
Clinical Trials on Progressive Stretching
-
Cairo UniversityCompletedAdhesive Capsulitis | Stretch | Physical NeglectEgypt
-
AdventHealth Translational Research InstituteNational Cancer Institute (NCI)RecruitingRectal Neoplasms | Colonic NeoplasmsUnited States
-
Oslo University HospitalCompletedCerebral Palsy, Spastic, DiplegicNorway
-
Vanderbilt UniversityTerminatedElbow Fracture | Upper Extremity Fracture | Fractures, Comminuted | Elbow Dislocation | Upper Extremity DislocationUnited States
-
State University of MaringáCompletedMultiple SclerosisBrazil
-
Riphah International UniversityEnrolling by invitation
-
Memorial Sloan Kettering Cancer CenterDuke UniversityCompleted
-
Riphah International UniversityCompletedDiabetes Mellitus Type 2Pakistan
-
AdventHealth Translational Research InstituteNational Cancer Institute (NCI)RecruitingColonic NeoplasmsUnited States
-
Memorial Sloan Kettering Cancer CenterDuke UniversityCompleted